|View printer-friendly version|
|July 23, 2013 7:52 a.m.|
|A "Network of Excellence" (NNE) Collaboration: Directed to Novel Therapeutic Approaches in Neurodegenerative Diseases|
Population growth and increased longevity are combining in a way that
has seen the prevalence of brain diseases grow significantly and the
burden on society has dramatically increased.
Working as an open-network, the NNE is directed towards the discovery and development of new treatments and approaches to counter the devastating effects of neurological, neurodegenerative and psychiatric illness. It brings the researchers together and provides a working interface with industry, where experts in drug development from Teva will interact with academic researchers in order to increase the potential to translate basic science into therapeutic options.
Research projects supported by the NNE are already providing some important clues towards progress in key treatment modalities. Some of these projects have already identified approaches to treatment which may modify the course and progression of diseases.
In Alzheimer's disease, where loss of memory and learning ability lead to most devastating effects, approaches to enhance memory are being explored. Additionally, Multiple Sclerosis and Huntington disease are two areas where new approaches that aim to stop or reverse the progression of the disease are being investigated.
"I want to beat Multiple Sclerosis and send my patients back to their
lives," said Professor
"This initiative is all about supporting academic research. Most of
these projects are at an early stage and significant development is
still required. What we have established is a very promising foundation
that I am confident will deliver advances in terms of approaches to
treatment." Said Dr.
"There is a new spirit of collaboration, which I hope will ultimately
lead to improvements for patients," said Prof.
"The NNE is an exciting collaboration that creates synergy between basic
science, started by universities and hospitals, with the knowledge and
resources from industry," said Professor
The National Network of Excellence in Neuroscience includes the following institutions:
Teva's Safe Harbor Statement under the
This release contains forward-looking statements, which express the
current beliefs and expectations of management. Such statements are
based on management’s current beliefs and expectations and involve a
number of known and unknown risks and uncertainties that could cause our
future results, performance or achievements to differ significantly from
the results, performance or achievements expressed or implied by such
forward-looking statements. Important factors that could cause or
contribute to such differences include risks relating to: our ability to
develop and commercialize additional pharmaceutical products,
competition for our innovative products, especially Copaxone® (including
competition from innovative orally-administered alternatives, as well as
from potential purported generic equivalents), competition for our
generic products (including from other pharmaceutical companies and as a
result of increased governmental pricing pressures), competition for our
specialty pharmaceutical businesses, our ability to achieve expected
results through our innovative R&D efforts, the effectiveness of our
patents and other protections for innovative products, decreasing
opportunities to obtain U.S. market exclusivity for significant new
generic products, our ability to identify, consummate and successfully
integrate acquisitions, the effects of increased leverage as a result of
recent acquisitions, the extent to which any manufacturing or quality
control problems damage our reputation for high quality production and
require costly remediation, our potential exposure to product liability
claims to the extent not covered by insurance, increased government
scrutiny in both the U.S. and